219 related articles for article (PubMed ID: 21322756)
1. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
Grisham RN; Berek J; Pfisterer J; Sabbatini P
Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
[TBL] [Abstract][Full Text] [Related]
2. A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients.
Battaglia A; Fossati M; Buzzonetti A; Scambia G; Fattorossi A
Immunol Lett; 2017 Nov; 191():35-39. PubMed ID: 28919454
[TBL] [Abstract][Full Text] [Related]
3. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
Bauerschlag DO; Schem C; Baumann K; Harter P; Hilpert F; Wagner U; du Bois A; Pfisterer J
Future Oncol; 2008 Dec; 4(6):769-73. PubMed ID: 19086842
[TBL] [Abstract][Full Text] [Related]
5. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.
Sabbatini P; Harter P; Scambia G; Sehouli J; Meier W; Wimberger P; Baumann KH; Kurzeder C; Schmalfeldt B; Cibula D; Bidzinski M; Casado A; Martoni A; Colombo N; Holloway RW; Selvaggi L; Li A; del Campo J; Cwiertka K; Pinter T; Vermorken JB; Pujade-Lauraine E; Scartoni S; Bertolotti M; Simonelli C; Capriati A; Maggi CA; Berek JS; Pfisterer J
J Clin Oncol; 2013 Apr; 31(12):1554-61. PubMed ID: 23478059
[TBL] [Abstract][Full Text] [Related]
6. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
Pfisterer J; du Bois A; Sehouli J; Loibl S; Reinartz S; Reuss A; Canzler U; Belau A; Jackisch C; Kimmig R; Wollschlaeger K; Heilmann V; Hilpert F
Ann Oncol; 2006 Oct; 17(10):1568-77. PubMed ID: 17005631
[TBL] [Abstract][Full Text] [Related]
7. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Schultes BC; Smith LM; Nicodemus CF
Clin Cancer Res; 2007 Jul; 13(13):4026; author reply 4026-7. PubMed ID: 17606738
[No Abstract] [Full Text] [Related]
9. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer.
Nicholson S; Bomphray CC; Thomas H; McIndoe A; Barton D; Gore M; George AJ
Cancer Immunol Immunother; 2004 Sep; 53(9):809-16. PubMed ID: 15127236
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Sabbatini P; Dupont J; Aghajanian C; Derosa F; Poynor E; Anderson S; Hensley M; Livingston P; Iasonos A; Spriggs D; McGuire W; Reinartz S; Schneider S; Grande C; Lele S; Rodabaugh K; Kepner J; Ferrone S; Odunsi K
Clin Cancer Res; 2006 Sep; 12(18):5503-10. PubMed ID: 17000686
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
Berek JS
Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
[TBL] [Abstract][Full Text] [Related]
13. Abagovomab for ovarian cancer.
Pfisterer J; Harter P; Simonelli C; Peters M; Berek J; Sabbatini P; du Bois A
Expert Opin Biol Ther; 2011 Mar; 11(3):395-403. PubMed ID: 21241213
[TBL] [Abstract][Full Text] [Related]
14. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
Wagner U; Köhler S; Reinartz S; Giffels P; Huober J; Renke K; Schlebusch H; Biersack HJ; Möbus V; Kreienberg R; Bauknecht T; Krebs D; Wallwiener D
Clin Cancer Res; 2001 May; 7(5):1154-62. PubMed ID: 11350879
[TBL] [Abstract][Full Text] [Related]
15. Antibody-based immunotherapy for ovarian cancer: where are we at?
Tse BW; Collins A; Oehler MK; Zippelius A; Heinzelmann-Schwarz VA
Ann Oncol; 2014 Feb; 25(2):322-31. PubMed ID: 24285017
[TBL] [Abstract][Full Text] [Related]
16. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer.
Schlebusch H; Wagner U; Grünn U; Schultes B
Hybridoma; 1995 Apr; 14(2):167-74. PubMed ID: 7590775
[TBL] [Abstract][Full Text] [Related]
17. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
Madiyalakan R; Sykes TR; Dharampaul S; Sykes CJ; Baum RP; Hör G; Noujaim AA
Hybridoma; 1995 Apr; 14(2):199-203. PubMed ID: 7590780
[TBL] [Abstract][Full Text] [Related]
18. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
[TBL] [Abstract][Full Text] [Related]
19. The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis.
Mei L; Hou Q; Fang F; Wang H
Eur J Gynaecol Oncol; 2016 Aug; 37(4):455-460. PubMed ID: 29894066
[TBL] [Abstract][Full Text] [Related]
20. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.
Ma J; Zhou L; Wang D
Jpn J Cancer Res; 2002 Jan; 93(1):78-84. PubMed ID: 11802811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
